Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5843426 | 0.98 | TSHR (0.62) | TSHRHSD17B10POLBTDP1SMN1; SMN2 | |
| SCHEMBL14393566 | 0.90 | ALDH1A1 (0.64) | HSD17B10ALDH1A1KMT2A | |
| SCHEMBL1726735 | 0.90 | TSHR (0.57) | TSHRHSD17B10POLBTDP1SMN1; SMN2 | |
| SCHEMBL2811459 | 0.89 | TSHR (0.56) | TSHRHSD17B10POLBTDP1SMN1; SMN2 | |
| SCHEMBL28191332 | 0.89 | TSHR (0.56) | TSHRHSD17B10POLBTDP1SMN1; SMN2 | |
| SCHEMBL26393724 | 0.88 | FAAH (0.55) | TSHRHSD17B10POLBTDP1ALDH1A1 | |
| SCHEMBL9633498 | 0.88 | FAAH (0.55) | TSHRHSD17B10POLBTDP1ALDH1A1 | |
| SCHEMBL84933 | 0.86 | TSHR (0.59) | TSHRHSD17B10POLBTDP1SMN1; SMN2 | |
| SCHEMBL15079103 | 0.85 | HSD17B10 (0.56) | TSHRHSD17B10POLBTDP1SMN1; SMN2 | |
| Sulfuric Acid SCHEMBL1819503 | 0.85 | TSHR (0.56) | TSHRHSD17B10POLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034020-B2 | Derivatives of butyric acid and uses thereof | THE UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCE (US) | 2006-04-25 | — | — | US | claimed |
| US-20040127564-A1 | Derivatives of butyric acid and uses thereof | THE UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES | 2004-07-01 | — | — | US | claimed |
| US-20020143056-A1 | Derivatives of butyric acid and uses thereof | THE UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES | 2002-10-03 | — | — | US | claimed |
| WO-2000073257-A1 | DERIVATIVES OF BUTYRIC ACID AND USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2000-12-07 | — | — | WO | claimed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| WO-2017176040-A1 | HETEROCYCLIC COMPOUND DECOMPOSING RAS AND USES THEREOF | 연세대학교 산학협력단 | 2017-10-12 | — | — | WO | disclosed |
| WO-2014165746-A1 | METHODS AND COMPOSITIONS USING ADAM10 INHIBITORS TO TREAT BACTERIAL INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8747904-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8287910-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7034020-B2 | Derivatives of butyric acid and uses thereof | THE UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCE (US) | 2006-04-25 | — | — | US | disclosed |
| US-20040127564-A1 | Derivatives of butyric acid and uses thereof | THE UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES | 2004-07-01 | — | — | US | disclosed |
| US-6664394-B2 | As inactivator of antigen- specific T cells is useful in the prophylaxis or therapy of autoimmune diseases, disorders involving an autoimmune component or neoplastic diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2003-12-16 | — | — | US | disclosed |
| US-20020143056-A1 | Derivatives of butyric acid and uses thereof | THE UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES | 2002-10-03 | — | — | US | disclosed |
| US-6407107-B1 | 4-(MORPHOLINO)ALKYL BUTANAMIDE DERIVATIVES; AUTOIMMUNE DISEASES; ANTICARCINOGENIC AGENTS | THE BOARD OF TRUSTEES OF THE UNVERSITY OF ARKANSAS | 2002-06-18 | — | — | US | disclosed |
| CN-1335849-A | Pyrrolopyrimidines as protein kinase inhibitors | BASF AG (DE) | 2002-02-13 | — | — | CN | disclosed |
| WO-2000073257-A1 | DERIVATIVES OF BUTYRIC ACID AND USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143056-A1 | Derivatives of butyric acid and uses thereof | CD4, NFATC1, GABRA4 | TSHR 2972/4885HSD17B10 969/4885POLB 3390/4885 |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | TSHR 415/4885HSD17B10 3157/4885POLB 2648/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | TSHR 395/4885HSD17B10 4571/4885POLB 3371/4885 |
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | TSHR 3319/4885HSD17B10 4042/4885POLB 6/4885 |
| US-20040127564-A1 | Derivatives of butyric acid and uses thereof | CD4, NFATC1, GABRA4 | TSHR 3006/4885HSD17B10 912/4885POLB 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.